Bicara's Ficerafusp Alfa Shows Strong Efficacy in HNSCC, Eyes Less Frequent Dosing
Event summary
- Bicara Therapeutics presented Phase 1b data showing 2000mg Q2W ficerafusp alfa with pembrolizumab achieved 48% ORR in 1L HPV-negative R/M HNSCC.
- 26% of patients achieved complete response, with 77% of responders showing ≥80% tumor shrinkage.
- Company plans to develop a loading and every-three-week maintenance dosing regimen pending regulatory alignment.
- Ongoing FORTIFI-HN01 Phase 3 trial continues with 1500mg weekly dosing.
- Data presented at 2026 Multidisciplinary Head and Neck Cancers Symposium.
The big picture
Bicara's data suggests potential for a more convenient dosing schedule while maintaining efficacy, which could enhance patient compliance and market adoption. The results position ficerafusp alfa as a potential leader in HPV-negative HNSCC treatment, though regulatory hurdles and competitive dynamics remain critical factors.
What we're watching
- Regulatory Alignment
- Whether Bicara can secure FDA agreement for the less frequent dosing regimen.
- Clinical Validation
- How the durability of responses in the Q2W regimen compares to the weekly dosing in the Phase 3 trial.
- Market Differentiation
- The competitive positioning of ficerafusp alfa against existing HNSCC treatments.
Related topics